FDA approves Pradaxa to prevent stroke in people with atrial fibrillation

Tweet

Pin It

FDA approves Pradaxa to prevent stroke in people with atrial fibrillation may spell the death knell for the upiquitous INR/anticoagulation clinics. If not pradaxa, perhaps a future agent. The hidden costs of transport, staffing, interpretation, and informing patients which are generated by INR clinics may be a good reason to encourage drugs like pradaxa. In the 21st century, INR clinics are an anachronism, IMHO.